Pharmacotherapy of prostatitis.
BACKGROUND
Prostatitis is a prevalent and morbid condition with a significant impact on a patient's quality of life. The four distinct prostatitis syndromes have different pathophysiologies, therapy and prognosis. Acute and chronic bacterial prostatitis is best treated with appropriate antibiotics that penetrate the prostate and kill the causative organisms. The most challenging category to treat is category III or chronic prostatitis/chronic pelvic pain syndrome.


METHODS
This review covers the categories of prostatitis and currently recommended therapies, as well as novel approaches on the horizon.


RESULTS
Knowledge of the current framework for the diagnosis and management of the diverse prostatitis spectrum.


CONCLUSIONS
Prostatitis is a diverse group of syndromes. Chronic prostatitis/chronic pelvic pain syndrome is a multifactorial syndrome that requires a multimodal approach to effectively treat the patient. The UPOINT technique is used to clinically phenotype these patients and drive the selection of multimodal therapy.
Snow
Devon C
DC
Glickman Urological and Kidney Institute, Cleveland Clinic, Desk Q10-1, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Shoskes
Daniel A
DA
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000529:Complementary Therapies; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D008517:Phytotherapy; D011472:Prostatitis / Q000145:classification* / Q000188:drug therapy* / Q000628:therapy
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents; D009465:Neuromuscular Agents